ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Gemphire Therapeutics Inc

Gemphire Therapeutics Inc (GEMP)

0,30
0,00
(0,00%)
Geschlossen 16 Januar 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,30
Gebot
0,30
Fragen
0,3169
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
0,30
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

GEMP Neueste Nachrichten

Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals

ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after...

Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals

ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of...

Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company

Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic...

Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Tri...

LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line...

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results

LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update

LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

LIVONIA, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

Gemphire Therapeutics Announces Workforce Reduction

LIVONIA, Mich., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

LIVONIA, Mich., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD

LIVONIA, Mich., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

GEMP - Frequently Asked Questions (FAQ)

What is the current Gemphire Therapeutics share price?
The current share price of Gemphire Therapeutics is US$ 0,30
What is the 1 year trading range for Gemphire Therapeutics share price?
Gemphire Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
AALAmerican Airlines Group Inc
US$ 18,07
(0,00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0,1326
(0,00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72,22
(0,00%)
0
AADIAadi Bioscience Inc
US$ 3,24
(0,00%)
0
AACGATA Creativity Global
US$ 1,03
(0,00%)
0
AALAmerican Airlines Group Inc
US$ 18,07
(0,00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0,1326
(0,00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72,22
(0,00%)
0
AADIAadi Bioscience Inc
US$ 3,24
(0,00%)
0
AACGATA Creativity Global
US$ 1,03
(0,00%)
0
AALAmerican Airlines Group Inc
US$ 18,07
(0,00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0,1326
(0,00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72,22
(0,00%)
0
AADIAadi Bioscience Inc
US$ 3,24
(0,00%)
0
AACGATA Creativity Global
US$ 1,03
(0,00%)
0
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock